Despite major advances in the diagnosis and treatment of coronary artery disease and congestive heart failure, sudden cardiac arrest (SCA) remains a major public health problem in the United States. 1 This is underscored by the fact that as the mortality from cardiovascular disease has declined over the last 40 years, the number of sudden deaths per year has remained fairly constant. What has appeared to change over this time is the arrhythmic cause of SCA with a declining frequency of ventricular fibrillation and an increasing incidence of pulseless electrical activity and asystole. 2 The latter may be a primary cause of SCA but could also reflect the cessation of electrical activity over time after cardiac arrest that originates as ventricular fibrillation. While some episodes of SCA occur during the acute phase of a myocardial infarction, the majority are primarily arrhythmic events that occur without clinical evidence of an acute coronary syndrome.
Clinical investigation has thus far focused on identifying and treating the patients at highest risk of SCA from lethal ventricular arrhythmias. Patients at highest risk include those having heart failure with depressed systolic left ventricular function and patients with inheritable genetic disorders placing them at high risk of SCA. Significant advances have been made in treating selected subgroups of patients. Nevertheless, there are several sobering observations regarding the current approaches that are available to identify and treat those at risk of SCA. First, as recently summarized, 3 nearly half of all sudden deaths occur in patients without a prior diagnosis of heart disease making the rapid initiation of cardiopulmonary resuscitation the only currently available approach to treat these patients (Table 1) . Of the equally large number developing SCA with established heart failure or stable ischemic heart disease, a minority (13-14%) have depressed left ventricular systolic function. Thus, few would be candidates to receive a primary prevention implantable cardiac defibrillator (ICD) based on current evidence-based guidelines. Finally, there has been considerable basic and clinical investigation into genetic abnormalities (e.g., ion channel abnormalities and hypertrophic cardiomyopathy) but these comprise a small number of the events (*2%). Thus, despite the magnitude of the problem and considerable clinical investigation, we currently have no additional approaches to identify the majority of patients who develop SCA. Although left ventricular ejection fraction (LVEF) has no direct relationship to the electrical activity of the heart and only identifies a small fraction of the patients at risk, it remains the standard of care for selecting high-risk patients most likely to benefit from primary prevention ICDs.
Because of these limitations, there continues to be considerable interest in developing novel imaging approaches to assess functional and anatomic substrate that is potentially associated with arrhythmic risk. These have largely focused on either quantifying myocardial sympathetic innervation or characterizing more detailed myocardial anatomic substrates such as fibrosis and myocardial scar volume. This review will primarily focus on studies using imaging to select patients at highest risk for primary prevention of SCA that already have a depressed LVEF. While encouraging results have been obtained, all of the imaging approaches remain investigational and none has been approved for selecting patients at risk of cause-specific mortality from SCA. Readers interested in the use of imaging to assess arrhythmic risk in inherited disorders associated with SCA are referred to a recent review. 4 
RESEARCH CHALLENGES FACING INVESTIGATORS EVALUATING IMAGING APPROACHES TO PREDICT SCA
The methodologies developed to use advanced cardiac imaging modalities to identify substrate factors associated with SCA are fairly straightforward. Nevertheless, the end-points used to define clinically relevant arrhythmic events vary widely among published studies making it difficult to pool observations on their prognostic value. Furthermore, the majority of studies are small and retrospective in nature. Several small studies have evaluated cause-specific mortality from sudden death using contemporary adjudication methods but most have evaluated composite primary end-points. While composite end-points are helpful in using an imaging approach to assess prognosis, they frequently include outcomes related to heart failure that may be of limited value in identifying patients most likely to benefit from device therapies to prevent arrhythmic events leading to SCA. An obvious example is that a single chamber primary prevention ICD will prevent SCA from ventricular fibrillation (VF) but it would not have an impact on death due to pump dysfunction. Thus, the ideal imaging approach should be able to predict the likelihood of developing SCA independently from the competing risk of death from heart failure. The second major problem facing clinical trials of imaging in predicting the risk of SCA relates to the increasing need to employ prospective observational studies that rely on surrogate end-points like appropriate ICD therapies. The clearest surrogate end-point for SCA would be ICD discharge for ventricular fibrillation. Defibrillation for fast ventricular tachycardia (VT [ 240 bpm, which is at times difficult to distinguish from VF on recorded ICD electrogram), is also felt to be a closer surrogate end-point for SCA. This is supported by the observation that the frequency of therapy for VF or fast VT approximate the benefit of primary prevention ICD device therapy on survival. 5 Nevertheless, the majority of trials evaluating novel imaging approaches have included all appropriate ICD therapies as surrogates for lethal ventricular arrhythmias which greatly overestimate the actual frequency of sudden death in the population at risk (at least threefold). It is now clear that the majority of ventricular arrhythmias treated with conventional ICD programming are short-lived and self-terminating without progressing to VF or sustained VT. For example, in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy, increasing the time to detect and treat ventricular arrhythmias not only reduced occurrence of appropriate ICD therapies (76%) but less aggressive programming surprisingly also improved survival. 6 Finally, most available studies evaluating imaging modalities that may help predict the risk of SCA are retrospective, have referral bias and, as stated above, employ composite primary end-points that commonly reflect a variety of adverse outcomes other than arrhythmic death. Most include patients with ischemic as well as nonischemic cardiomyopathy and many also include both patients receiving ICDs for secondary prevention of SCA and patients receiving ICDs for primary prevention. Very few studies have attempted to develop multiple-parameter risk models combining biomarkers, high-risk clinical variables and imaging. Of the prediction models developed, none have yet been validated in prospective clinical trials. These limitations are not unique to imaging studies and are also present in many studies that employ alternate approaches for risk stratification for SCA such as those assessing aspects of cardiac electrical activity and cardiac biomarkers. 2 The remainder of this review will summarize the current status of imaging autonomic dysfunction and myocardial scar to predict the risk of developing life-threatening arrhythmias in primary prevention ICD candidates with acquired forms of heart disease.
MYOCARDIAL SYMPATHETIC DENERVATION AND THE RISK OF SCA
Alterations in cardiac sympathetic activity have been linked to disease progression and increased mortality in cardiovascular disease. 7 Advances in cardiac molecular imaging have resulted in the development of radiolabeled norepinephrine analogs that can quantify myocardial sympathetic innervation in vivo. These are normally taken up into the presynaptic sympathetic nerve terminal by the norepinephrine transporter (Figure 1) . Two have been studied the most extensively. 123 I-meta-iodobenzylguanidine ( 123 I-mIBG) is a SPECT tracer which has been approved by the FDA for imaging cardiac sympathetic innervation to determine prognosis in patients with heart failure. The investigational positron emitting agent 11 C-meta-hydroxyephedrine ( 11 C-HED) is the principal PET tracer which has been used in research studies quantifying regional sympathetic denervation. Despite an ever growing body of evidence demonstrating an association between Figure 1 . Schematic of sympathetic transmission. Schematic of sympathetic transmission and neuronal uptake of 11 C-HED ( 11 C-meta-Hydroxyephedrine) and 123 I-mIBG ( 123 I-Metaiodobenzylguanidine) for imaging of sympathetic neuronal innervation. Norepinephrine (NE) is synthesized and packaged in the presynaptic sympathetic nerve terminals and released into the synaptic cleft. Released NE binds to postsynaptic receptors, is taken up via the presynaptic norepinephrine transporter (NET) for repackaging or is released into the circulation and exits the heart through the coronary venous circulation (not show). Both 11 C-HED and 123 I-mIBG are taken up into the presynaptic nerve terminals using the NETdependent mechanism. VMAT vesicular monoamine transporter, DOPA 3,4-dihydroxyphenylalanine. Modified and reproduced with permission from Malhotra et al. 55 radiotracer-based assessment of cardiac sympathetic denervation with ventricular arrhythmias and SCA, none are currently approved to select patients for cardiac device therapy.
Global Cardiac Sympathetic Denervation and Event-Free Survival
Initial studies evaluating the prognostic significance of cardiac sympathetic denervation examined the relationship between outcomes and the global heart-tomediastinum ratio (HMR) of 123 I-mIBG in small clinical populations of mixed ischemic and nonischemic cardiomyopathy. In a cohort of 90 patients with cardiomyopathy, Merlet et al found that the HMR was the strongest predictor of survival over short-term follow-up. 8 These findings were subsequently expanded to show that the 123 I-mIBG HMR was the most significant clinical predictor of cardiac mortality. 9 The predictive capacity of global 123 I-mIBG was independent of the etiology of left ventricular dysfunction, and also provided prognostic value among those with only mildly reduced LVEF (40-50%). 9 These initial studies paved the way for the multicenter ADMIRE-HF study (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure), which is the largest prospective study evaluating global 123 ImIBG uptake and clinical outcomes. In this study, planar 123 I-mIBG and SPECT perfusion imaging were performed in 961 patients with New York Heart Association class II or III heart failure and LVEF B 35%. 10 The majority of patients (66%) had ischemic cardiomyopathy. Over a median follow-up of 17 months, the primary composite end-point (including heart failure progression, all arrhythmic events, and cardiac death) occurred more frequently among those with a global reduction in myocardial 123 I-mIBG uptake (prospectively defined as a late HMR \ 1.6). Although the frequency of arrhythmic events was significantly higher among those with a HMR \ 1.6, the vast majority of events were nonsustained VT. Sudden death, resuscitated SCA and appropriate ICD discharges (including shock as well as anti-tachycardia pacing) were a small portion of the total composite end-points (21%). 10 Quantification of regional defects in a subgroup of patients did not provide any additional value in predicting prognosis.
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A sub-analysis of the ADMIRE-HF study explored whether 123 I-mIBG HMR improved risk stratification over LVEF. ADMIRE-HF LVEF values reported by the core laboratory (some [ 35%) were stratified by a late HMR of 1.6 and composite end-points were estimated in each group. 11 A late HMR of \1.6 conferred a greater risk of death and arrhythmic events across all LVEF subgroups. Interestingly, among subjects with relatively preserved function (LVEF [ 40%), a HMR [ 1.6 was associated with an excellent prognosis with no mortality or arrhythmic events in the follow-up period. In contrast, individuals having an LVEF [ 40% and a late HMR \ 1.6 had a 7.5% per 100 person-years risk of death and composite arrhythmic events. This retrospective post hoc analysis raises the possibility that imaging sympathetic innervation in patients with only mildly depressed LV function could aid in identifying the large number of patients at risk of SCA who are currently not considered candidates based on LVEF. 3, 12 Verschure et al performed a patient level metaanalysis to determine the prognostic end-point that was most highly associated with altered global 123 I-mIBG uptake. 13 Over a mean follow-up of 37 months, the HMR was able to predict all categories of cardiac events. The strongest predictive values were for composite cardiac events, all cause mortality, and total cardiac mortality. Interestingly, the weakest univariate predictor of global 123 I-mIBG HMR was for arrhythmic events. In multivariate analysis, only heart failure class and age were independently associated with arrhythmias.
Global Cardiac Sympathetic Denervation and Cause-Specific Mortality From Sudden Death and/or Surrogate Arrhythmic EndPoints
Tamaki et al showed that cardiac 123 I-mIBG imaging could also predict the subsequent development of cause-specific mortality from SCA in 106 patients with a LVEF \ 40%.
14 Three indices of sympathetic denervation were derived from 123 I-mIBG imaging-early HMR (at 20 minutes), delayed HMR (at 200 minutes), and the 123 I-mIBG washout ratio (between 20 and 200 minutes after injection). Over an average follow-up of 5.4 years, there were 18 events and each of the 123 I-mIBG indices were predictors of SCA. 14, 15 In multivariate analysis, only the washout ratio and LVEF remained independent predictors of SCA. Patients with a rapid washout ratio ([27%) had a significantly greater risk of SCA (hazards ratio: 4.8, 95% confidence interval: 1.6-14.8). This predictive value was also seen among subjects with a LVEF [ 35%.
14 Other 123 I-mIBG indices as well as signal-averaged electrocardiogram, heart rate variability, and QT dispersion were not independent predictors of SCA. It should be noted that there were several exclusion criteria for this study, most notably the use of beta-blockers at the time of imaging. Since optimal medical therapy can favorably improve the washout ratio, [16] [17] [18] the generalizability of this early study to the contemporary management of patients that are usually imaged on medical therapy for heart failure remains unclear. Despite this caveat, this study is particularly significant since it is the only one available that did not include surrogate end-points such as ICD therapies and only included cause-specific mortality from SCA as its primary end-point.
A post hoc analysis of the ADMIRE-HF study showed a relationship between HMR on planar imaging and arrhythmic events (defined as a composite of SCA, appropriate ICD therapy, resuscitated cardiac arrest, or sustained ventricular tachycardia). In this analysis, Al Badarin et al evaluated 778 patients from the original ADMIRE-HF cohort who did not have an ICD at the time of 123 I-mIBG imaging. 19 These patients had a composite arrhythmic event rate of 6.9% and 9.4% at 1 and 2 years, respectively. A HMR \ 1.6 (hazards ratio: 3.5, 95% confidence interval: 1.5-8), an LVEF \ 25% (hazards ratio: 1.9, 95% confidence interval: 1.2-3.0), and a systolic blood pressure \ 120 mmHg (hazards ratio: 1.2, 95% confidence interval: 1.0-1.4) were independent predictors of arrhythmic events. The ADMIRE-HF risk score developed using these variables demonstrated that a small subset of the population without them (*20%) was at low risk for arrhythmic events (discussed subsequently).
Regional Cardiac Sympathetic Denervation, SCA, and Arrhythmic Events
Global myocardial norepinephrine uptake is reduced from increased washout arising from increased myocardial sympathetic tone in viable myocardium as well as areas of regional sympathetic denervation. Some studies have evaluated whether inhomogeneity in sympathetic innervation increases the risk of SCA or surrogate arrhythmic end-points (Figure 1 ). Inhomogeneity in myocardial sympathetic innervation can occur in areas subjected to reversible ischemia as well as in fibrotic myocardial scars. 20 Due to this, the 123 I-mIBG defect size in patients with coronary disease frequently exceeds infarct volume. This is best demonstrated in patients undergoing reperfusion with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 21, 22 Prominent regional denervation also develops following chronic repetitive ischemia without infarction and has been found in animal models of hibernating myocardium with both 123 I-mIBG 23 and 11 C-HED. 24 In preclinical studies, viable dysfunctional myocardial regions can exhibit partial sympathetic denervation, 25 evidence of reinnervation as reflected by sympathetic nerve sprouting 25, 26 and alterations in beta adrenergic receptor density. 27 The translational relevance of these findings is underscored by the fact that animal models of viable dysfunctional myocardium exhibit one of the highest rates of spontaneous SCA from VF during brief sympathetic activation in the absence of infarction. 28, 29 Since regional myocardial sympathetic denervation is more technically challenging to quantify, there are fewer studies that have evaluated its prognostic significance. Nevertheless, the available data suggest that inhomogeneity and/or the extent of sympathetic denervation in humans may be more directly related to arrhythmic end-points and sudden death. Bax et al provided one of the first clinical studies exploring the relation between regional sympathetic denervation and inducible arrhythmic events in 50 patients having an LVEF B 40% who were referred for electrophysiological study for unexplained syncope or nonsustained VT. 30 The 30 patients with a positive electrophysiological study had a significantly greater late 123 I-mIBG SPECT summed defect score compared to those with a negative electrophysiological study. There were no differences between groups in global 123 I-mIBG uptake (early or late HMR). The only independent predictor of a positive electrophysiological study (sustained VT) was the late summed 123 I-mIBG defect score reflecting the extent of regional denervation. Along similar lines, a recent study found reduced regional 123 I-mIBG uptake in scar border zones to predict VT inducibility during an electrophysiological study. 31 The ability of regional sympathetic denervation assessed using 123 I-mIBG and SPECT Technetium-99m perfusion imaging to predict spontaneous arrhythmic events (appropriate ICD therapies) was evaluated in a heterogeneous population of 116 patients. This cohort included patients with both ischemic and nonischemic cardiomyopathy as well as those receiving an ICD for primary as well as secondary prevention of SCA. 32 After an average follow-up period of 23 months, appropriate ICD therapy (shock or anti-tachycardia pacing) occurred in 21% of the patients. Late 123 I-mIBG SPECT defect size and ICD implantation for secondary prevention (not primary prevention) were the only independent predictors of ICD therapy and all cause cardiac mortality. Appropriate ICD therapies were more prevalent among those with large 123 I-mIBG defects (summed rest score [ 26) when compared to smaller defects.
Recently, PET with 11 C-HED was employed to quantify the extent of regional sympathetic denervation and predict the risk of SCA in primary prevention ICD candidates with ischemic cardiomyopathy. 33, 34 This trial was motivated by the fact that PET imaging has significant technical advantages allowing regional defect size to be quantified more readily than SPECT 123 ImIBG. The Prediction of ARrhythmic Events with Positron Emission Tomography trial, was a prospective observational cohort study powered to evaluate whether the volume of denervated myocardium, infarct volume or viable hibernating myocardium could predict increased cause-specific mortality from SCA as its primary end-point. The study enrolled 204 patients, who underwent PET assessment of myocardial perfusion ( 13 NH 3 -ammonia retention), myocardial denervation ( 11 C-HED), and viability ( 18 F-2-deoxyglucose during a glucose insulin clamp). After an average follow-up period of 4.1 years, thirty-three patients experienced SCA. This end-point included adjudicated arrhythmic death (SCA) or ICD discharge for aborted arrhythmic death (ventricular fibrillation or VT [ 240 beats/minutes). Other device therapies including treatments for VT at rates \ 240 (ATP or ICD discharge) were not considered SCA surrogates. Patients developing SCA had a significantly greater volume of denervated myocardium as well as greater viable denervated myocardium when compared to those without SCA (Figure 2 ). Kaplan-Meier survival analysis demonstrated that both denervated and viable denervated myocardium predicted time to SCA. Every 1% increase in the volume of the denervated myocardium was associated with a 5.7% increase in the risk of SCA. Patients in the highest tertile of denervation had an SCA rate of 6.7% per year. In a multivariate analysis, the magnitude of denervated myocardium was the only independent predictor of SCA from PET. Other multivariate predictors of SCA included, left ventricular size (end-diastolic volume index), serum creatinine, and the inability to take an angiotensin converting enzyme inhibitor or angiotensin receptor blocker. The LVEF was not predictive of appropriate ICD therapy in this population nor was infarct volume assessed with 18 F-2-deoxyglucose during a glucose insulin clamp. The 11 C-HED retention in normally innervated myocardial regions was not different among those with and without SCA in part reflecting the high prevalence of optimal medical therapy in these patients. A post hoc analysis found integrated 11 C-HED uptake throughout the entire left ventricle to be predictive of SCA (area under the curve: 0.76 vs. 0.78 for 11 C-HED defect size).
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In summary, there is a growing body of literature demonstrating that imaging myocardial sympathetic innervation using a variety of radiopharmaceuticals can provide prognostic information regarding the course of ischemic and nonischemic cardiomyopathy. Much of this reflects the fact that increases in myocardial sympathetic nerve activity are associated with reduced myocardial uptake of norepinephrine analogs reflecting the progression of congestive heart failure. These global abnormalities correlate with surrogate end-points related to hospitalization as well as mortality from pump dysfunction. More recent studies have begun to evaluate cause-specific end-points that are associated with arrhythmic death. While none of these methods has been validated in prospectively studied cohorts, the regional quantification of denervated myocardium in viable as well as infarcted regions appears to hold promise in differentiating patients at low and high risk of arrhythmic death.
MYOCARDIAL SCAR AND THE RISK OF SCA
Fatal ventricular arrhythmias from VT that degenerate into VF are felt to originate in myocardial scars and surrounding border regions. Electrophysiological studies have suggested a greater risk for SCA among those with ischemic cardiomyopathy who have multiple areas of transmural infarction when compared to those with less extensive scars. 36 In nonischemic cardiomyopathy, the presence of midwall fibrosis has been reported to predict those at risk SCA. 37 Thus, imaging myocardial scar may compliment LVEF to provide incremental prognostic value in terms of SCA. Both cardiac magnetic resonance and cardiac radionuclide imaging have been extensively studied in this regard.
Identification of Scar on Cardiac Magnetic Resonance
Cardiac magnetic resonance is an excellent tool for myocardial tissue characterization and has the additional advantage of greater spatial and temporal resolution as compared to SPECT or PET. Cardiac magnetic resonance with late gadolinium enhancement can readily quantify regions of myocardial scarring (Figure 3) . The presence and extent of scar on gadolinium-enhanced cardiac magnetic resonance has been shown to be related to composite cardiovascular outcomes in both ischemic cardiomyopathy 38 and nonischemic cardiomyopathy. [39] [40] [41] Electrophysiological studies have suggested that heterogeneity with islands of viable myocardium and fibrotic tissue are a particularly arrhythmogenic substrate which cardiac magnetic resonance can identify as areas of intermediate intensity on LGE images. These regions are commonly referred to as the 'gray zone.' They have been shown to correlate with reduced QRS voltage when mapping patients with inducible ventricular arrhythmias. 42 Thus, using cardiac magnetic resonance, the infarcted myocardial region can be divided into a central core infarct zone and a periinfarct gray zone extending both circumferentially to the viable remote region as well as transmurally to the viable subepicardium. While both regions can be quantified using semi-automated methods 43 there is currently no consensus among studies regarding the specific criteria used to define the gray zone. Investigators have used the signal intensity or the full-width-half-maximal approaches for determining core infarct from peri-infarct gray zone on late gadolinium-enhanced cardiac magnetic resonance. Core infarct and peri-infarct gray zones can be identified as areas of the myocardium with signal intensity C3 standard deviations and signal intensity between 2 and 3 standard deviations of the remote myocardial region, respectively. 43, 44 Others have employed a full-width-half-maximal approach where core infarcts are identified as areas C50% of the maximal signal intensity of the infarct, and peri-infarct gray zones as areas with signal intensity greater than the maximum signal intensity of viable myocardium but \50% of maximal signal intensity of the infarct.
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The Relation Between Scar on Cardiac Magnetic Resonance, Arrhythmias, and SCA The extent of late gadolinium enhancement on cardiac magnetic resonance has been shown to be associated with arrhythmic outcomes, in heterogeneous populations referred for electrophysiological study as well as ICD placement for primary and secondary prevention. An early study of 48 patients with ischemic cardiomyopathy referred for electrophysiological study reported a significantly greater infarct mass and surface area among those with inducible VT as opposed to noninducible patients. 38 Infarct mass and surface area were independent predictors of inducible VT while LVEF was not. In support of this, a recent study found that patients receiving appropriate ICD therapies had an absolute infarct size of 39 grams while those with no ICD therapy had an infarct size of 18 grams. 45 Given the pathophysiological significance of infarct heterogeneity in ventricular arrhythmias, recent cardiac magnetic resonance studies have focused on quantifying the scar gray zone. A small study of patients undergoing ICD implants found that those with inducible monomorphic VT during electrophysiological testing had significantly larger peri-infarct gray zones when compared to those without (19 vs. 13 grams, P = 0.015). 46 LVEF, infarct size, and indices of left ventricular remodeling were not different. In another study 47 where appropriate ICD therapies were delivered to *20% of patients with ischemic cardiomyopathy (median followup of 8.5 months), the gray zone was the only independent predictor of VT (hazards ratio = 1.5, P = 0.04). Like other studies, LVEF was not predictive of appropriate ICD therapy in this population. In a similar patient population, all measures of scar by cardiac magnetic resonance (total, core infarct, and gray zone) were predictive of ventricular arrhythmias. 48 In this cohort, quantifying the core infarct and gray zone did not improve the prediction of VT in comparison to total scar size. While these studies report an association between scar characteristics on cardiac magnetic resonance with arrhythmic events, all used either inducible VT or aggregate ICD therapies as surrogates for life-threatening ventricular arrhythmias. None of them evaluated SCA as an end-point directly.
More recent studies have evaluated scar on cardiac magnetic resonance in relation to SCA and surrogate arrhythmic end-points more closely linked to SCA. The Prospective Observational Study of Implantable Cardioverter Defibrillators trial prospectively evaluated 235 patients with ischemic or nonischemic cardiomyopathy that received primary prevention ICDs. 41 All patients underwent cardiac magnetic resonance with blinded quantification of core infarct and gray zone. Nineteen percent of the study population developed arrhythmic outcomes (ICD therapy for sustained VT [ 180 beats per minute or VF) or cardiac death. The gray zone on cardiac magnetic resonance and elevated high-sensitive c-reactive protein were the only independent predictors of outcome on multivariate analysis.
Other studies have failed to show relation between the gray zone and arrhythmias. In primary prevention, ICD patients with ischemic and nonischemic cardiomyopathy, Gao et al found that total scar was the only significant predictor (hazards ratio: 1.4, P = 0.001) of patients experiencing a composite end-point which included appropriate ICD therapy, aborted SCA, and sudden cardiac death. 39 The total cardiac magnetic resonance scar also had a high negative predictive value (86%) for predicting event-free survival. Scar gray zone did not stratify patients developing the composite endpoint. Similarly, another study enrolling patients with ischemic and nonischemic cardiomyopathy (with an LVEF above and below 30%), reported that a scar size of [5% of the LV myocardium was the only independent predictor of SCA or ICD therapy. The gray zone was not predictive of arrhythmic outcomes after adjusting for scar size.
In summary, currently available studies highlight the potential usefulness of cardiac magnetic resonancebased assessment of scar to assess cardiovascular risk for composite end-points including arrhythmic events and appropriate ICD therapies. While promising, there are limitations related to employing the available data to predict the risk of lethal arrhythmic events. First, multiple approaches for scar quantification have been proposed 49 and no consensus exists on the optimal methodology for risk stratification. The lack of a consistent approach is compounded by the large variability reported in the assessment of core and periinfarct (gray) regions. 48, 49 Second, like imaging myocardial sympathetic innervation, the majority of studies use primary end-points that were composite and include ICD therapies for many ventricular arrhythmias that could be self-terminating and not degenerate into lethal arrhythmias such as ventricular fibrillation. Thus, while the available studies demonstrate an association between myocardial scar on cardiac magnetic resonance and cardiac mortality as well as composite arrhythmic events that include multiple appropriate ICD therapies, the evidence supporting cardiac magnetic resonance to predict cause-specific mortality from sudden death remains limited at the present time.
Scar on Radionuclide Imaging and Relationship with Arrhythmic Events
While most recent literature has focused on assessing the relation between scar and arrhythmic events using cardiac magnetic resonance, previous studies have evaluated the relationship of scar on nuclear myocardial 50 Over a follow-up of 30 months, 13% of the patients experienced SCA. While they had significantly lower LVEF and greater left ventricular volumes, SPECT infarct size was the strongest predictor of SCA (hazards ratio: 6.3, 95% confidence interval: 1.8-22.8). In a secondary prevention population study, consecutive survivors of SCA with ischemic cardiomyopathy were enrolled to examine the relationship among ischemia, viability, scar, and recurrent arrhythmic events. 51 Those with extensive scar by SPECT (defined as scar involving [1 vascular territory) had significantly higher recurrent event rates when compared to those with less extensive or no scar (54% vs. 16%, P \ 0.05). On multivariate analysis, an extensive scar and LVEF B 30% were the only independent predictors of death and recurrent ventricular arrhythmias.
The presence of myocardial scar on SPECT has been shown to further risk stratify patients with low HMR (\1.6) on 123 I-mIBG imaging in patients with nonischemic cardiomyopathy. 52 Among 317 patients from the ADMIRE-HF cohort, those with a late HMR \ 1.6 but a summed rest score B 8 had fewer episodes of sustained VT, resuscitated SCA, and appropriate ICD therapies when compared to those with a summed rest score [ 8 (3.9% vs. 11.9%, P = 0.001). Hou et al recently reported the prevalence of appropriate ICD therapy, VT, and VF over an average follow-up of 15 months and SPECT parameters. 53 Patients who experienced the composite end-point (39%) had significantly lower LVEF (24% vs. 35%, P \ 0.005) and larger myocardial scar area (35% vs. 12%, P \ 0.005). Neither LVEF nor scar area predicted the occurrence of arrhythmic events on multivariate analysis. These findings are similar to those from the PAREPET study. In this study, PET infarct size (assessed using 18 F-2-deoxyglucose during a glucose insulin clamp) was not an independent predictor of arrhythmic events which included adjudicated sudden death or aborted SCA (ICD discharge for VF or VT [ 240 bpm) 34 . In summary, the currently available data from studies using radionuclide imaging is consistent in showing that scar volume is related to all cause cardiovascular mortality in patients with a depressed ejection fraction. While scar volume is also predictive of receiving appropriate ICD therapies, many of these may be treating self-terminating events that may not lead to SCA. Thus, when evaluating arrhythmic death and a more restrictive set of ICD surrogate end-points felt to be more directly associated with SCA, the PAREPET trial did not demonstrate a relation between scar volume and event-free survival.
IMAGING-BASED RISK MODELS FOR PREDICTING LIFE-THREATENING ARRHYTHMIAS
Risk prediction models incorporating multiple imaging parameters along with clinically relevant variables have only been evaluated in a few studies but have shown promise in developing risk scores that may better improve our ability to predict subgroups of patients at highest risk for arrhythmic events and cause-specific mortality from SCA. Several of these risk models are briefly summarized in Table 2 . While it is understandable that such an approach may have a low sensitivity, the high specificity conferred by this approach could provide a negative predictive value that is sufficient to identify those with a depressed ejection fraction at low risk of arrhythmic events. Several promising approaches are discussed in greater detail below.
An initial sub-analysis of the ADMIRE-HF cohort demonstrated the combined value of imaging scar and sympathetic denervation for predicting composite arrhythmic events (sustained VT, resuscitated cardiac arrest, and appropriate ICD therapy). 52 Arrhythmic events developed in 63 of 929 patients were ICD therapies (73%). When analyzed by etiology of heart failure, the HMR and infarct size (summed rest score: SRS) stratified those with nonischemic but not ischemic cardiomyopathy. Individuals with a HMR C 1.6 and an infarct size of\12% of the LV had no arrhythmic events (high negative predictive value). Patients with both a low HMR and high scar burden had the highest risk (12%) of arrhythmic events. A subsequent analysis of patients without an ICD at the time of 123 I-mIBG imaging confirmed that a late HMR \ 1.6, an LVEF \ 25% along with systolic blood pressure were independent predictors of composite events. 19 The authors used these parameters to develop an ADMIRE-HF risk score to stratify the population (Figure 4) . In another study, Kawai et al prospectively evaluated the value of a risk score determined from delayed HMR and WR, on 123 I-mIBG imaging, in predicting SCA. 54 The authors divided late HMR and WR into 6 grades from 0 to 5, according to the degree of deviation from control values, and based on these scores, the patients were divided into 3 groups: low (1 to 4), intermediate (5 to 7), and high (8 to 10). In this study, a total of 16 of 81 patients experienced SCA during an average follow-up period of 7 years. Patients with a low 123 I-mIBG risk score had no events (high negative predictive value) but these progressively increased with increasing score category (intermediate 19% and high 36%, P = 0.001).
The PAREPET study developed a risk model to predict SCA using optimized cut points for the four independent predictors of arrhythmic death identified from multivariate analysis. 34 These included the amount of denervated myocardium (on 11 C-HED PET), LV enddiastolic volume, serum creatinine, and lack of angiotensin inhibition. A PAREPET risk score was developed based on the number of risk factors present (0, 1 or C2). The annual rate of SCA was \1% when no risk factors were present, 4%/year with 1 risk factor, and 12%/year for those with C2 risk factors ( Figure 5) . Importantly, nearly half of this primary prevention ICD population with ischemic cardiomyopathy was identified as low risk for SCA using this approach.
Cardiac MR has also been employed to develop a cardiovascular risk model. The PROSE-ICD study developed a risk model to predict arrhythmic events using late gadolinium-enhanced cardiac magnetic resonance. 41 In this study, high sensitivity c-reactive protein and scar gray zone volume on late gadolinium-enhanced cardiac magnetic resonance were predictive of arrhythmic events. The gray zone and high sensitivity c-reactive protein were divided into tertiles to stratify the population. Patients in the lowest tertile of both gray zone and high sensitivity c-reactive protein had an annualized event rate of 0.7% compared to the intermediate (5.6%/ year) and highest risk groups (16%/year).
Collectively, these studies highlight the fact that a combination of risk factors including clinical, biomarker, and imaging parameters (some employing multiple modalities) may provide a greater precision to risk stratify patients for SCA as opposed to single imaging parameters. While these approaches show great promise as risk prediction tools, none have yet been validated in prospective studies.
SUMMARY
The use of newer cardiac imaging modalities to predict the risk of SCA in high-risk subpopulations of patients with established heart disease and depressed left ventricular function has advanced substantially. Virtually all of these approaches are based upon quantitative rather than subjective image analysis. Thus, if prospectively validated, high-throughput automated imaging analysis will be required for clinicians to incorporate the results into predictive algorithms as continuous variables of risk in practice. Assessing scar volume appears to correlate with composite cardiovascular outcomes including total cardiac mortality. The ability of scar volume to identify patients at risk of arrhythmic death using surrogate end-points that more closely correlate Figure 4 . Prediction of arrhythmic events by the ADMIRE-HF score risk model. ADMIRE-HF risk score comprised of LVEF\25%, late HMR \ 1.6 and systolic blood pressure (SBP) of \120 mmHg, 120-139 mmHg and C140 mmHg. Patients with a low risk score had a significantly lower event rate (2%) at 24 months of follow-up when compared to those with intermediate (10%) and high risk scores (16%) (P = 0.001). The annualized event rate among patients with a low ADMIRE-HF risk score was *1%/year. Reproduced with permission from Al Badarin et al. 19 Figure 5. Sudden cardiac arrest risk factor model from PAREPET. PAREPET risk score based on retrospective analysis using the four independent risk parameters from multivariate analysis. These included the percent of the left ventricle that was denervated, left ventricular end-diastolic volume index, serum creatinine, and the inability to take in angiotensin converting enzyme inhibitor. Cut points were obtained from univariate models for each continuous parameter or the presence or absence of angiotensin inhibition therapy. Kaplan-Meier curves demonstrate highly significant differences in the incidence of SCA in relation to the number of risk factors present (P \ 0.0001). Subjects with no risk factors (blue, 44% of cohort) had an annual rate of SCA\1%. Those with two or more risk factors (red, 20% of cohort) had an annual risk of SCA increased to *12%. Patients with one risk factor (green, 36% of cohort) had an intermediate risk of SCA (*4%/year). With permission from Fallavollita et al. 34 with the development of arrhythmic death remains untested. Analysis of myocardial sympathetic innervation currently has similar issues regarding the prediction of composite end-points not directly related to arrhythmic death. Nevertheless, several studies evaluating 123 ImIBG washout in relation to SCA 54 as well as imaging regional denervation with PET in ischemic cardiomyopathy 34 provide promising data that support the ability of imaging myocardial sympathetic innervation to assess the relative risk of cause-specific mortality from SCA in patients with a depressed ejection fraction. The next step is to prospectively validate risk prediction models to predict SCA and compare strategies based upon competing imaging modalities in a head to head fashion. This will hopefully lead to an improved approach to identify patients at risk of sudden cardiac death that can be employed to identify those at risk in the large group of patients that have relatively preserved systolic function.
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